Novel Immune-Modulating Antibodies for Cancer and Autoimmune Diseases
LEXINGTON & CAMBRIDGE, Mass., May 25th, 2021 – Alloy Therapeutics (“Alloy”) and Pyxis Oncology (“Pyxis”) today announced the formation of a joint venture named Kyma Therapeutics to develop immune-modulating antibodies for novel targets in cancer and autoimmune diseases. Voxall Therapeutics will advance programs directed to immune-modulating targets identified by Pyxis. Alloy Discovery Services will generate […]
Alloy Therapeutics Raises $75 Million in Series C Financing to Advance Collaborative Biotechnology Ecosystem
Funds to be used to advance platforms and resources used by scientific entrepreneurs to turn ideas into biological medicines.
Maze Therapeutics and Alloy Therapeutics Form Broadwing Bio to Develop Antibody Therapies for Genetically Validated Targets in Ophthalmic Diseases
Maze Therapeutics and Alloy Therapeutics announced the formation of Broadwing Bio to develop targeted antibody therapies for the treatment of ophthalmic diseases.